# A Randomised, Open-label Trial to Assess the Safety and Efficacy of Switching to Tenofovir-emtricitabine or Abacavir-lamivudine: The STEAL Study

> **NCT00192634** · PHASE4 · COMPLETED · sponsor: **Kirby Institute** · enrollment: 357 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Emtricitabine 200mg - Tenofovir 300mg
- **DRUG:** Abacavir 600mg - Lamivudine 300mg

## Key facts

- **NCT ID:** NCT00192634
- **Lead sponsor:** Kirby Institute
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-12
- **Primary completion:** 2008-08
- **Final completion:** 2008-08
- **Target enrollment:** 357 (ACTUAL)
- **Last updated:** 2011-05-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00192634

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00192634, "A Randomised, Open-label Trial to Assess the Safety and Efficacy of Switching to Tenofovir-emtricitabine or Abacavir-lamivudine: The STEAL Study". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00192634. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*